[Four-connected Nanhua Bio: Cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage] On September 22, Nanhua Bio (000504.SZ) issued a stock trading risk warning announcement stating that the company's current main business is biomedicine and energy conservation and environmental protection. Among them, the biomedicine segment mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells. It also cooperates with a number of clinical research institutions to provide them with cell preparation, testing and other services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage. The energy-saving and environmental protection segment is mainly engaged in lithium carbonate business, scrap steel renewable resources and supporting processing and sales.